Ascendis Pharma A/S
Ascendis Pharma A/S Fundamental Analysis
Ascendis Pharma A/S (ASND) shows moderate financial fundamentals with a PE ratio of -53.64, profit margin of -31.72%, and ROE of 1.28%. The company generates $0.7B in annual revenue with strong year-over-year growth of 36.34%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 96.0/100 based on profitability, valuation, growth, and balance sheet metrics. The A grade reflects excellent fundamentals and strong overall stability.
Fundamental Health Score
We analyze ASND's fundamental strength across five key dimensions:
Efficiency Score
WeakASND struggles to generate sufficient returns from assets.
Valuation Score
ExcellentASND trades at attractive valuation levels.
Growth Score
ExcellentASND delivers strong and consistent growth momentum.
Financial Health Score
ExcellentASND maintains a strong and stable balance sheet.
Profitability Score
ModerateASND maintains healthy but balanced margins.
Key Financial Metrics
Is ASND Expensive or Cheap?
P/E Ratio
ASND trades at -53.64 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, ASND's PEG of -23.85 indicates potential undervaluation.
Price to Book
The market values Ascendis Pharma A/S at -75.06 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at -148.23 times EBITDA. This is generally considered low.
How Well Does ASND Make Money?
Net Profit Margin
For every $100 in sales, Ascendis Pharma A/S keeps $-31.72 as profit after all expenses.
Operating Margin
Core operations generate -19.00 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $1.28 in profit for every $100 of shareholder equity.
ROA
Ascendis Pharma A/S generates $-17.49 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Ascendis Pharma A/S generates limited operating cash flow of $51.17M, signaling weaker underlying cash strength.
Free Cash Flow
Ascendis Pharma A/S produces free cash flow of $42.78M, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $0.70 in free cash annually.
FCF Yield
ASND converts 0.35% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-53.64
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-23.85
vs 25 benchmark
P/B Ratio
Price to book value ratio
-75.06
vs 25 benchmark
P/S Ratio
Price to sales ratio
17.02
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
-5.35
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.04
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
1.28
vs 25 benchmark
ROA
Return on assets percentage
-0.17
vs 25 benchmark
ROCE
Return on capital employed
-0.59
vs 25 benchmark
How ASND Stacks Against Its Sector Peers
| Metric | ASND Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -53.64 | 28.45 | Better (Cheaper) |
| ROE | 127.54% | 763.00% | Weak |
| Net Margin | -31.72% | -45265.00% (disorted) | Weak |
| Debt/Equity | -5.35 | 0.34 | Strong (Low Leverage) |
| Current Ratio | 1.04 | 2795.60 | Neutral |
| ROA | -17.49% | -16588.00% (disorted) | Weak |
ASND outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Ascendis Pharma A/S's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
2084.14%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
-39.32%
Industry Style: Defensive, Growth, Innovation
DecliningFCF CAGR
-39.81%
Industry Style: Defensive, Growth, Innovation
Declining